Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

NCT01794429 on ClinicalTrials.gov · last registry update 2015-06-24

A small phase 3 — 45 participants, against a typical 424. The sponsor logged completion for June 2015. Primary outcome, as filed: Weight loss. exenatide is approved in the US, but not for metabolic syndrome and obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Bjorn H. Ebdrup
Sponsor type: Other
Enrollment: 45
Started: 2013-02
Primary completion: 2015-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight loss

Conditions studied

Obesity · Metabolic Syndrome X · Drug-induced Obesity · Schizophrenia

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.